Brain atrophy in multiple sclerosis: what we know and would like to know (Q36722172)

15 August 2017

1 reference

title

Brain atrophy in multiple sclerosis: what we know and would like to know (English)

1 reference

15 August 2017

0 references

J H Simon

1

1 reference

15 August 2017

publication date

1 December 2006

1 reference

Multiple Sclerosis Journal

15 August 2017

published in

1 reference

15 August 2017

volume

12

1 reference

15 August 2017

issue

6

1 reference

15 August 2017

page(s)

679-687

1 reference

Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070823

Eight-year follow-up study of brain atrophy in patients with MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070823

Brain and spinal cord atrophy in multiple sclerosis: role as a surrogate measure of disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070823

Distinct patterns of multiple sclerosis pathology indicates heterogeneity on pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070823

Magnetic resonance studies of abnormalities in the normal appearing white matter and grey matter in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070823

Axon damage and repair in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070823

Axonal degeneration and progressive neurologic disability in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070823

Axonal loss in multiple sclerosis: a pathological survey of the corticospinal and sensory tracts

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070823

A longitudinal study of callosal atrophy and interhemispheric dysfunction in relapsing-remitting multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070823

MRI/MRS of corpus callosum in patients with clinically isolated syndrome suggestive of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070823

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070823

A longitudinal study of brain atrophy in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070823

Transcallosal bands: a sign of neuronal tract degeneration in early MS?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070823

Serial magnetization transfer imaging in acute optic neuritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070823

Size-selective neuronal changes in the anterior optic pathways suggest a differential susceptibility to injury in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070823

Axon pathology in neurological disease: a neglected therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070823

Macrophage responses and myelin clearance during Wallerian degeneration: relevance to immune-mediated demyelination

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070823

Diffusion tensor imaging detects early Wallerian degeneration of the pyramidal tract after ischemic stroke.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070823

Gradual loss of myelin and formation of an astrocytic scar during Wallerian degeneration in the human spinal cord.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070823

Axonal loss in normal-appearing white matter in a patient with acute MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070823

Thalamic neurodegeneration in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070823

Thalamic neurodegeneration in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070823

Evidence of early cortical atrophy in MS: relevance to white matter changes and disability

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070823

Brain tissue volume changes in relapsing-remitting multiple sclerosis: correlation with lesion load

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070823

Subpial demyelination in the cerebral cortex of multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070823

Focal thinning of the cerebral cortex in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070823

Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070823

Overview of primary progressive multiple sclerosis (PPMS): similarities and differences from other forms of MS, diagnostic criteria, pros and cons of progressive diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070823

Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070823

Brain damage when multiple sclerosis is diagnosed clinically

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070823

Progressive ventricular enlargement in patients with clinically isolated syndromes is associated with the early development of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070823

MRI predictors of early conversion to clinically definite MS in the CHAMPS placebo group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070823

Accelerated evolution of brain atrophy and "black holes" in MS patients with APOE-epsilon 4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070823

From enhancing lesions to brain atrophy in relapsing MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070823

Brain atrophy in clinically early relapsing-remitting multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070823

Enhancing magnetic resonance imaging lesions and cerebral atrophy in patients with relapsing multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070823

Brain atrophy in multiple sclerosis: impact of lesions and of damage of whole brain tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070823

Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070823

Interferon-beta-1b slows progression of atrophy in RRMS: Three-year follow-up in NAb- and NAb+ patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070823

The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. European Study Group on Interferon beta-1b in secondary progressive multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070823

Short-term brain volume change in relapsing-remitting multiple sclerosis: effect of glatiramer acetate and implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070823

Interferon beta-1a in primary progressive MS: an exploratory, randomized, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070823

Whole brain volume changes in patients with progressive MS treated with cladribine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070823

Quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody Campath 1H.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070823

Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070823

Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070823

21 January 2018

Identifiers

DOI

10.1177/1352458506070823

1 reference

release_mnf7zy7j2fgznkcahgnwcvm7jy

15 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/mnf7zy7j2fgznkcahgnwcvm7jy

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference